NeoGenomics wraps up takeover of liquid biopsy platform company Inivata

TAGS

NeoGenomics, a US-based cancer diagnostics and pharma services company, has wrapped up its previously announced $390 million takeover of Inivata, a liquid platform company based in Cambridge, England.

The deal was announced in May 2021 by NeoGenomics as it exercised a purchase option to acquire the remaining equity interest in Inivata. A year prior to that, NeoGenomics made an equity investment of $25 million for a minority stake in Inivata.

Inivata developed a platform called InVision that is said to unlock vital genomic information from a simple blood draw to guide and customize , monitor response, and also detect relapse.

See also  RWE advances UK solar and battery pipelines with JBM Solar acquisition

The company’s technology is based on research from the Cancer Research UK Cambridge Institute, .

Inivata will now operate as a liquid biopsy focused unit alongside NeoGenomics’ clinical, pharma and informatics divisions.

The company’s CEO – will be the president of Inivata and will report to NeoGenomics CEO Mark Mallon.

NeoGenomics wraps up takeover of liquid biopsy platform company Inivata

NeoGenomics wraps up takeover of liquid biopsy platform company Inivata. Photo courtesy of fernando zhiminaicela from Pixabay.

Commenting on NeoGenomics acquisition of Inivata, Mark Mallon said: “Inivata has been a strategically important partner for us over the last year and we are excited today to officially welcome the company’s world class team of professionals and liquid biopsy capabilities to NeoGenomics.

See also  Know foods for Nail health on how to fix split nails or cracked nails

“We are particularly enthusiastic about Inivata’s highly sensitive RaDaR assay, targeting the emerging and significant opportunity for minimal residual disease testing. We plan on leveraging our established oncology diagnostics leadership position, human capital, strong pharma and clinical market relationships, and robust balance sheet to accelerate the development of this assay.

See also  Tampa General Hospital opens new AI-driven center CareComm

“The addition of Inivata bolsters our leading market position today and further establishes us as a leader in the rapidly evolving liquid biopsy testing space.”


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

CATEGORIES
TAGS
Share This